Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a ...

On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth ...

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

Yahoo Finance anchor Josh Lipton tracks Wednesday's top moving stocks and biggest market stories in this Market Minute. Hims ...

March 9 (Reuters) - Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans ...

Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & ...

Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will ...

Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.